FRANKLIN, Mass., Nov. 9 /PRNewswire-FirstCall/ -- Sontra Medical
Corporation (Nasdaq: SONT) announced today that is has received a Phase 1 U.S.
Army SBIR $70,000 grant that will be used to investigate the transdermal
delivery of a dengue vaccine with the SonoPrep skin permeation device. The
U.S. Army is developing a vaccine for the dengue pandemic which is a mosquito-
born viral disease found in tropical regions of the world afflicting tens of
millions of people and hospitalizing 500,000 persons, mostly children.
Pre-clinical studies under this Phase 1 program will be conducted over a
six month period ending in May 2006. At the Army's option, the program could
be extended through a Phase 2 Army SBIIR award to be granted in October 2006,
which would result in additional award of approximately $800,000 for funding
human clinical studies.
"We believe that the immune response for vaccines can be optimized through
topical delivery with SonoPrep and are excited to be working with world
renowned immunology experts at the U.S. Army," stated Thomas W. Davison, PhD,
Sontra's President and Chief Executive Officer. Sontra's SonoPrep ultrasonic
skin permeation device employs low frequency ultrasound to penetrate the
skin's outermost layer, the stratum corneum. This simple and fast (average 15
second) treatment creates an imperceptible window through the skin that
enables molecules to pass through with 100 times greater efficiency than
intact skin. SonoPrep has the potential to deliver vaccines to the viable
epidermis to activate the Langerhan cells, which invoke a powerful immune
response.
About Sontra Medical Corporation (http://www.sontra.com)
Sontra Medical Corporation is a technology leader in transdermal science.
Sontra's SonoPrep ultrasound-mediated skin permeation technology combined with
technical competencies in transdermal drug formulation, delivery systems and
biosensors is creating a new paradigm in transdermal drug delivery and
diagnosis. The SonoPrep technology is being developed for several billion
dollar market opportunities, including continuous glucose monitoring and the
transdermal delivery of large molecule drugs and vaccines. Sontra is currently
marketing the SonoPrep device and procedure tray for use with topical
lidocaine to achieve rapid (within five minutes) skin anesthesia.
Investor Relations Contact:
Sean Moran, Chief Financial Officer
508-530-0334
SonoPrep is a registered trademark of Sontra Medical Corporation. All
other company, product or service names mentioned herein are the trademarks or
registered trademarks of their respective owners.
This press release contains forward-looking statements, which address a
variety of subjects including, for example, the expected benefits and efficacy
of the SonoPrep device in connection with diagnostics, vaccine delivery,
glucose monitoring and transdermal drug delivery, the expected results of the
research collaboration with the U.S. Army and ability to deliver vaccines
topically; the expected market opportunities, distribution and market
acceptance of the SonoPrep device and technology, the expected size of the
markets for the SonoPrep device and technology, and Sontra's business,
research, product development, regulatory approval, marketing and distribution
plans and strategies. Statements that are not historical facts, including
statements about our beliefs and expectations, are forward-looking statements.
Such statements are based on our current expectations and are subject to a
number of factors and uncertainties, which could cause actual results to
differ materially from those described in the forward-looking statements. The
following important factors and uncertainties, among others, could cause
actual results to differ materially from those described in these forward-
looking statements: adverse results in research collaborations, product
development, clinical trials, product evaluations, commercialization efforts,
product distribution and market acceptance; difficulties or delays in
obtaining regulatory approvals to market products resulting from development
efforts; difficulties or delays associated with sources of regulatory-approved
transdermal drugs and vaccines; failure to obtain and maintain patent
protection for discoveries; commercial limitations imposed by patents owned or
controlled by third parties; dependence upon strategic partners and third-
party distributors to develop, commercialize, market and sell products based
on our work; the commercial success of products; and the requirement for
substantial funding to conduct research and development and to expand
commercialization, distribution and marketing activities. For detailed
information about factors that could cause actual results to differ materially
from those described in the forward-looking statements, please refer to
Sontra's filings with the Securities and Exchange Commission, including
Sontra's most recent Quarterly Report on Form 10-QSB. Forward-looking
statements represent management's current expectations and are inherently
uncertain. We do not undertake any obligation to update forward-looking
statements made by us.
SOURCE Sontra Medical Corporation
 back to top
Related links:
http://www.sontra.com
CONTACT:
Sean Moran, Chief Financial Officer of Sontra
Medical Corporation, +1-508-530-0334
|
